biotech
biotech Articles
AcelRx intends to pursue an ARX-04 indication for moderate-to-severe pain in a medically supervised setting. However, this might be farther out than investors anticipated.
Published:
Last Updated:
Quidel is considered a bet on flu season. The analyst team over at Canaccord Genuity likes Quidel quite a bit.
Published:
Last Updated:
Atara Biotherapeutics announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting in patients with end stage renal disease.
Published:
Last Updated:
Akebia Therapeutics led the bulls early on Monday following news of what looks like a big commercialization partnership in Asia.
Published:
Last Updated:
Bluebird Bio, Idera Pharmaceuticals and others stood out from other biotech stock with incredible gains or losses over the course of the past week.
Published:
Last Updated:
Cara Therapeutics saw its stock rise in Wednesday’s session on statistically significant Phase 2 results, but the delight of investors may be short lived.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these selected stocks for this settlement date.
Published:
Last Updated:
Baxalta was rising in Wednesday’s trading session on news of a key U.S. Food and Drug Administration (FDA) approval.
Published:
Last Updated:
Aeterna Zentaris has amended is filing with the U.S. Securities and Exchange Commission (SEC) for its secondary offering.
Published:
Last Updated:
TherapeuticsMDwas leading the health care sector in Tuesday’s session on positive top-line results from one of its late-stage trials.
Published:
Last Updated:
Onconova Therapeutics led the bulls early in Tuesday’s trading session on positive data from an ongoing Phase 1/2 clinical trial.
Published:
Last Updated:
A new Jefferies research report features some solid new growth stock calls that make good sense for people looking to perhaps replace stocks that underperformed this past year.
Published:
Last Updated:
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Published:
Last Updated:
Bluebird Bio absolutely tanked in Monday's trading session, based on preclinical and manufacturing data from the American Society of Hematology Annual Meeting.
Published:
Last Updated:
Threshold Pharmaceuticals watched its stock completely collapse in Monday’s session after a joint late-stage study failed to yield positive results.
Published:
Last Updated: